– USA, TN – Amytrx Therapeutics, a leading biopharmaceutical company specializing in the development of novel therapies for dermatology and inflammation, announced the additions of Dr. Michael Howell and Dr. Satish Joshi to its Board of Directors, bringing a wealth of experience and expertise to the company.
Their scientific background and business acumen will play a pivotal role in advancing the company’s mission to bring innovative treatments to market, with a primary focus on AMTX-100, a groundbreaking anti-inflammatory peptide.
About Dr. Michael Howell
Dr. Michael Howell, a renowned immunologist with more than 20 years of experience in allergy, autoimmunity, dermatology, inflammatory, and oncology diseases, has a distinguished record of contributions to the dermatology field. Dr. Howell has played a pivotal role in numerous clinical trials and has published extensively on topics related to dermatological and immunological conditions. He also participated in the development of many biological and small-molecule drugs currently on the market or in development. His extensive knowledge of the field will be invaluable as Amytrx Therapeutics continues its journey to revolutionize care for inflammatory skin diseases.
About Dr. Satish Joshi
Dr. Satish Joshi, a respected technocrat in peptide solutions with over 25 years of experience in the peptide API business, has been at the forefront of peptide product development throughout his career. His work has led to several successful strategic business initiatives in the peptide and biochemical therapeutic industry. Dr. Joshi’s expertise will be instrumental as Amytrx Therapeutics strives to develop strategic partnerships that further the development of therapeutics for patients suffering from inflammation-related conditions.
About Amytrx Therapeutics, Inc.
Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some the world’s most debilitating diseases.
For more information: https://www.amytrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.